XML 71 R54.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Acquisitions - Narrative (Details) € in Millions, $ in Millions																						1 Months Ended	3 Months Ended		12 Months Ended			24 Months Ended	30 Months Ended	31 Months Ended
	Oct. 11, 2019 USD ($) shares	Aug. 01, 2019 USD ($)	Jun. 14, 2019 USD ($)	Mar. 28, 2019 USD ($)	Dec. 14, 2018 USD ($)	Nov. 13, 2018 USD ($)	Jul. 31, 2018 USD ($) shares	May 23, 2018 USD ($)	May 18, 2018 USD ($)	Apr. 06, 2018 USD ($)	Feb. 14, 2018 USD ($)	Oct. 02, 2017 USD ($)	Sep. 01, 2017	Aug. 04, 2017 USD ($)	Jul. 03, 2017 USD ($)	Jul. 01, 2017	Jun. 16, 2017	May 23, 2017 USD ($) shares	May 19, 2017 USD ($)	May 01, 2017 USD ($)	Jan. 31, 2017 USD ($) item	Sep. 30, 2017 USD ($)	Dec. 31, 2019 USD ($)	Sep. 30, 2019 USD ($)	Dec. 31, 2019 USD ($)	Dec. 31, 2018 USD ($)	Dec. 31, 2017 USD ($)	Dec. 31, 2017 USD ($) shares	Dec. 31, 2019 USD ($)	Dec. 31, 2019 USD ($)	Oct. 11, 2019 EUR (€)	Sep. 30, 2017 AUD ($)
Business Acquisition [Line Items]
Payments to acquire intangible assets																									$ 3,324,000	$ 3,012,000	$ 2,577,000
Impairment																									3,300,000	657,000	809,000
Contingent liability																							$ 48,088,000		48,088,000	58,486,000			$ 48,088,000	$ 48,088,000
Impairment and other charges																									23,750,000	657,000	809,000
QX Medical, LLC
Business Acquisition [Line Items]
Payments to acquire intangible assets									$ 750,000
NinePoint Medical, Inc.
Business Acquisition [Line Items]
Option to purchase outstanding equity, up to										100.00%
Total purchase price										$ 10,000,000
Loan from acquisition										$ 10,500,000
Interest rate on loan										9.00%
Net sales related to acquisition																									2,900,000	3,000,000.0
Impairment and other charges																							20,500,000		20,500,000
Write off of accrued interest																							$ (1,600,000)		(1,600,000)
Sugan Co, Ltd.
Business Acquisition [Line Items]
Term of right to manufacture and sell certain products																			4 years
Customer Lists | Sugan Co, Ltd.
Business Acquisition [Line Items]
Intangibles																			$ 1,200,000
Useful life																			5 years
Distribution agreements | QX Medical, LLC
Business Acquisition [Line Items]
Useful life									10 years
Intellectual Property | IntelliMedical Technologies Pty Ltd
Business Acquisition [Line Items]
Total purchase price																						$ 11,900,000
Contingent liability																																$ 15.0
Current royalty rate													6.00%
Intellectual Property | Lazarus Medical Technologies, LLC
Business Acquisition [Line Items]
Payments to acquire intangible assets																														$ 620,000
Useful life																	15 years
License agreements | Pleuratech ApS
Business Acquisition [Line Items]
Payments to acquire intangible assets																													$ 2,000,000.0
Useful life																15 years
Impairment																									$ 1,800,000
Fluidx
Business Acquisition [Line Items]
Payments to acquire shares				$ 2,000,000
Ownership percentage																							11.60%		11.60%				11.60%	11.60%
Cagent Vascular, LLC
Business Acquisition [Line Items]
Preferred limited liability company units (in units) | shares							1,786,000																					3,000,000
Payments to acquire shares							$ 2,200,000																					$ 3,000,000.0
Ownership percentage																							19.50%		19.50%				19.50%	19.50%
Fusion Medical, Inc.
Business Acquisition [Line Items]
Preferred limited liability company units (in units) | shares																		182,000
Payments to acquire shares																		$ 2,500,000
Ownership percentage																		19.50%
Equity method investment																		$ 2,500,000
Selio
Business Acquisition [Line Items]
Loan from acquisition																							$ 250,000		$ 250,000				$ 250,000	$ 250,000
Interest rate on loan	5.00%
Ownership percentage	19.50%																														19.50%
Equity method investment	$ 2,600,000
Selio | Maximum
Business Acquisition [Line Items]
Loan commitment from acquisition | €																															€ 2
Selio | Ordinary shares
Business Acquisition [Line Items]
Shares acquired (in shares) | shares	3,900
Term of option to purchase equity	45 days
Selio | C Ordinary shares
Business Acquisition [Line Items]
Shares acquired (in shares) | shares	1,365
Fibrovein Holdings Limited
Business Acquisition [Line Items]
Purchase consideration, upfront payment		$ 13,700,000
Contingent liability		934,000
Fibrovein Holdings Limited | Developed technology
Business Acquisition [Line Items]
Intangibles		$ 10,428,000
Weighted average useful life		12 years
Fibrovein Holdings Limited | STD Pharmaceutical Products Limited
Business Acquisition [Line Items]
Ownership percentage		100.00%
Brightwater
Business Acquisition [Line Items]
Purchase consideration, upfront payment			$ 35,000,000
Working capital adjustment			$ 39,000
Weighted average useful life			12 years 10 months 24 days
Brightwater | Achievement of CE Certification
Business Acquisition [Line Items]
Earn-out payments			$ 5,000,000
Brightwater | Achievement of Sales Milestones
Business Acquisition [Line Items]
Earn-out payments			10,000,000
Brightwater | Developed technology
Business Acquisition [Line Items]
Intangibles			$ 31,960,000
Weighted average useful life			13 years
Brightwater | Trademarks
Business Acquisition [Line Items]
Intangibles			$ 250,000
Weighted average useful life			5 years
Brightwater | Customer Lists
Business Acquisition [Line Items]
Intangibles			$ 83,000
Weighted average useful life			1 year
Vascular Insights
Business Acquisition [Line Items]
Purchase consideration, upfront payment					$ 40,000,000
Working capital adjustment																								$ 15,000
Weighted average useful life					11 years 9 months 18 days
Contingent liability					$ 20,000,000
Net sales related to acquisition																									7,500,000
Vascular Insights | Developed technology
Business Acquisition [Line Items]
Intangibles					$ 32,750,000
Useful life					12 years
Vascular Insights | Trademarks
Business Acquisition [Line Items]
Intangibles					$ 1,410,000
Useful life					9 years
Vascular Insights | Customer Lists
Business Acquisition [Line Items]
Intangibles					$ 840,000
Useful life					8 years
Cianna Medical
Business Acquisition [Line Items]
Purchase consideration, upfront payment						$ 135,000,000
Working capital adjustment						$ 1,200,000
Weighted average useful life						10 years 8 months 12 days
Net sales related to acquisition																									49,500,000	6,300,000
Acquisition-related costs																										3,500,000
Cianna Medical | Achievement of Supply Chain and Scalability Metrics
Business Acquisition [Line Items]
Earn-out payments						$ 15,000,000
Cianna Medical | Annual Net Sales Milestone
Business Acquisition [Line Items]
Earn-out payments						50,000,000
Cianna Medical | Developed technology
Business Acquisition [Line Items]
Intangibles						$ 134,510,000
Useful life						11 years
Cianna Medical | Trademarks
Business Acquisition [Line Items]
Intangibles						$ 7,080,000
Useful life						10 years
Cianna Medical | Customer Lists
Business Acquisition [Line Items]
Intangibles						$ 3,330,000
Useful life						8 years
DirectACCESS Medical, LLC
Business Acquisition [Line Items]
Total purchase price								$ 7,300,000
Weighted average useful life								9 years 10 months 24 days
DirectACCESS Medical, LLC | Developed technology
Business Acquisition [Line Items]
Intangibles								$ 4,840,000
Useful life								10 years
DirectACCESS Medical, LLC | Trademarks
Business Acquisition [Line Items]
Intangibles								$ 400,000
Useful life								10 years
DirectACCESS Medical, LLC | Customer Lists
Business Acquisition [Line Items]
Intangibles								$ 120,000
Useful life								5 years
Becton, Dickinson and Company
Business Acquisition [Line Items]
Total purchase price											$ 100,300,000
Weighted average useful life											8 years
Contingent liability											$ 1,600,000
Net sales related to acquisition																									46,800,000	42,100,000
Acquisition-related costs																										1,800,000
Becton, Dickinson and Company | Developed technology
Business Acquisition [Line Items]
Intangibles											$ 74,000,000
Useful life											8 years
Becton, Dickinson and Company | Trademarks
Business Acquisition [Line Items]
Intangibles											$ 4,900,000
Useful life											9 years
Becton, Dickinson and Company | Customer Lists
Business Acquisition [Line Items]
Intangibles											$ 4,200,000
Useful life											7 years
ITL Healthcare Pty Ltd
Business Acquisition [Line Items]
Total purchase price												$ 11,300,000
Net sales related to acquisition																									7,700,000	8,000,000.0	3,300,000
ITL Healthcare Pty Ltd | Customer Lists
Business Acquisition [Line Items]
Intangibles												$ 5,940,000
Useful life												7 years
Laurane Medical S.A.S.
Business Acquisition [Line Items]
Total purchase price														$ 16,500,000
Weighted average useful life														11 years 10 months 24 days
Contingent liability														$ 5,500,000
Laurane Medical S.A.S. | Developed technology
Business Acquisition [Line Items]
Intangibles														$ 14,920,000
Useful life														12 years
Laurane Medical S.A.S. | Customer Lists
Business Acquisition [Line Items]
Intangibles														$ 120,000
Useful life														1 year
Osseon LLC
Business Acquisition [Line Items]
Total purchase price															$ 6,800,000
Weighted average useful life															9 years
Net sales related to acquisition																									1,700,000	2,100,000	942,000
Osseon LLC | Developed technology
Business Acquisition [Line Items]
Intangibles															$ 5,400,000
Useful life															9 years
Osseon LLC | Customer Lists
Business Acquisition [Line Items]
Intangibles															$ 200,000
Useful life															8 years
Vascular Access Technologies, Inc.
Business Acquisition [Line Items]
Total purchase price																				$ 5,000,000.0
Contingent liability																				4,900,000
Vascular Access Technologies, Inc. | Developed technology
Business Acquisition [Line Items]
Intangibles																				$ 7,800,000
Useful life																				15 years
Argon Medical Devices, Inc.
Business Acquisition [Line Items]
Total purchase price																					$ 10,100,000
Weighted average useful life																					6 years
Net sales related to acquisition																									46,800,000	45,500,000	41,200,000
Acquisition-related costs																											2,600,000
Purchase price adjustment																					$ (797,000)
Argon Medical Devices, Inc. | Developed technology
Business Acquisition [Line Items]
Intangibles																					$ 2,200,000
Useful life																					7 years
Argon Medical Devices, Inc. | Trademarks
Business Acquisition [Line Items]
Intangibles																					$ 900,000
Useful life																					5 years
Argon Medical Devices, Inc. | Customer Lists
Business Acquisition [Line Items]
Intangibles																					$ 1,500,000
Useful life																					5 years
Argon Medical Devices, Inc. | Preliminary Allocation
Business Acquisition [Line Items]
Total purchase price																					$ 10,900,000
Catheter Connections, Inc.
Business Acquisition [Line Items]
Number of patents acquired | item																					40
Total purchase price																					$ 38,000,000
Weighted average useful life																					11 years 8 months 12 days
Net sales related to acquisition																									$ 15,900,000	$ 13,700,000	10,000,000.0
Acquisition-related costs																											$ 482,000
Catheter Connections, Inc. | Developed technology
Business Acquisition [Line Items]
Intangibles																					$ 21,100,000
Useful life																					12 years
Catheter Connections, Inc. | Trademarks
Business Acquisition [Line Items]
Intangibles																					$ 2,900,000
Useful life																					10 years
Catheter Connections, Inc. | Customer Lists
Business Acquisition [Line Items]
Intangibles																					$ 700,000
Useful life																					8 years

X

- Definition

Business Acquisition, Option To Acquire Percentage of Voting Interests

+ References

No definition available.

+ Details

Name:	mmsi_BusinessAcquisitionOptionToAcquirePercentageofVotingInterests
Namespace Prefix:	mmsi_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Business Combination, Initial Working Capital Adjustment

+ References

No definition available.

+ Details

Name:	mmsi_BusinessCombinationInitialWorkingCapitalAdjustment
Namespace Prefix:	mmsi_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Current Royalty Rate

+ References

No definition available.

+ Details

Name:	mmsi_CurrentRoyaltyRate
Namespace Prefix:	mmsi_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Equity Method Investment, Limited Liability Company (LLC) Units

+ References

No definition available.

+ Details

Name:	mmsi_EquityMethodInvestmentLimitedLiabilityCompanyLLCUnits
Namespace Prefix:	mmsi_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Loan commitment amount to parties associated with the reporting entity.

+ References

No definition available.

+ Details

Name:	mmsi_LoanCommitmentRelatedParties
Namespace Prefix:	mmsi_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Definition

Notes Receivable, Interest Rate, Stated Percentage

+ References

No definition available.

+ Details

Name:	mmsi_NotesReceivableInterestRateStatedPercentage
Namespace Prefix:	mmsi_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Number of Patents Acquired

+ References

No definition available.

+ Details

Name:	mmsi_NumberofPatentsAcquired
Namespace Prefix:	mmsi_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Right to Manufacture and Sell Certain Products, Term

+ References

No definition available.

+ Details

Name:	mmsi_RighttoManufactureandSellCertainProductsTerm
Namespace Prefix:	mmsi_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

X

- Definition

The period within which the option to purchase ordinary shares commences from the date of approval of product.

+ References

No definition available.

+ Details

Name:	mmsi_TermOfOptionToPurchaseEquityFromReceivalOfApprovalOfProduct
Namespace Prefix:	mmsi_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 1
-Subparagraph (a)(3)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275

+ Details

Name:	us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
Namespace Prefix:	us-gaap_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 45
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109226348&loc=d3e2420-110228

+ Details

Name:	us-gaap_AssetImpairmentCharges
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Number of shares of equity interests issued or issuable to acquire entity.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 1
-Subparagraph (b)(4)
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479

+ Details

Name:	us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
Namespace Prefix:	us-gaap_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_BusinessAcquisitionLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 25
-Paragraph 23
-URI http://asc.fasb.org/extlink&oid=116868678&loc=d3e1043-128460

+ Details

Name:	us-gaap_BusinessCombinationAcquisitionRelatedCosts
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 30
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=116859721&loc=d3e6613-128477

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 30
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=116859721&loc=d3e6578-128477

+ Details

Name:	us-gaap_BusinessCombinationConsiderationTransferred1
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

For contingent consideration arrangements recognized in connection with a business combination, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 1
-Subparagraph (c)(3)
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479

+ Details

Name:	us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Definition

Amount of liability recognized arising from contingent consideration in a business combination.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 1
-Subparagraph (c)(1)
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 35
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 25
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476

+ Details

Name:	us-gaap_BusinessCombinationContingentConsiderationLiability
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Definition

This element represents the amount of revenue of the acquiree since the acquisition date included in the consolidated income statement for the reporting period.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (h)(1)
-URI http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463

+ Details

Name:	us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

This element represents the amount of any measurement period adjustment (as defined) realized during the reporting period to items of consideration transferred in connection with a business combination for which the initial accounting was incomplete.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 4A
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=116869197&loc=SL65897772-128472

+ Details

Name:	us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

The amount of identifiable intangible assets recognized as of the acquisition date.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 55
-Paragraph 37
-URI http://asc.fasb.org/extlink&oid=116868840&loc=d3e2207-128464

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=116869197&loc=d3e4845-128472

+ Details

Name:	us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

X

- Definition

The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

+ Details

Name:	us-gaap_EquityMethodInvestmentOwnershipPercentage
Namespace Prefix:	us-gaap_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	instant

X

- Definition

This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 25
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8813-108599

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.12)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name:	us-gaap_EquityMethodInvestments
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

X

- Definition

Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.

+ References

No definition available.

+ Details

Name:	us-gaap_FiniteLivedIntangibleAssetUsefulLife
Namespace Prefix:	us-gaap_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

X

- Definition

The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 3
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275

+ Details

Name:	us-gaap_ImpairmentOfIntangibleAssetsFinitelived
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

The increase (decrease) during the reporting period in the amount due from borrowers for interest payments.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585

+ Details

Name:	us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Amounts due from parties associated with the reporting entity as evidenced by a written promise to pay, due after 1 year (or 1 business cycle).

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(k)(1))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(3)(a)(2))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(11))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name:	us-gaap_NotesReceivableRelatedPartiesNoncurrent
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

X

- Definition

The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 1
-Subparagraph (b)(1)
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 13
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585

+ Details

Name:	us-gaap_PaymentsToAcquireBusinessesGross
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 13
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585

+ Details

Name:	us-gaap_PaymentsToAcquireEquityMethodInvestments
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 13
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585

+ Details

Name:	us-gaap_PaymentsToAcquireIntangibleAssets
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Percentage of subsidiary's or equity investee's stock owned by parent company before stock transaction.

+ References

No definition available.

+ Details

Name:	us-gaap_SaleOfStockPercentageOfOwnershipBeforeTransaction
Namespace Prefix:	us-gaap_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

X

- Details

Name:	srt_CounterpartyNameAxis=mmsi_QXMedicalLLCMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_CounterpartyNameAxis=mmsi_NinePointMedicalInc.Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_CounterpartyNameAxis=mmsi_SuganCoLtd.Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerListsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DistributionRightsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_IntellectualPropertyMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_CounterpartyNameAxis=mmsi_IntelliMedicalTechnologiesPtyLtdMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_CounterpartyNameAxis=mmsi_LazarusMedicalTechnologiesLLCMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_CounterpartyNameAxis=mmsi_PleuratechApSMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=mmsi_FluidxMedicalTechnologyLLCMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=mmsi_CagentVascularLLCMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=mmsi_FusionMedicalInc.Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_BusinessAcquisitionAxis=mmsi_SelioMedicalLimitedSelioMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_EquityInterestIssuedOrIssuableByTypeAxis=mmsi_OrdinarySharesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_EquityInterestIssuedOrIssuableByTypeAxis=mmsi_COrdinarySharesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_BusinessAcquisitionAxis=mmsi_FibroveinHoldingsLimitedMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_OwnershipAxis=mmsi_STDPharmaceuticalProductsLimitedMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_BusinessAcquisitionAxis=mmsi_BrightwaterMedicalInc.Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_ContingentConsiderationByTypeAxis=mmsi_AchievementofCECertificationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_ContingentConsiderationByTypeAxis=mmsi_AchievementofSalesMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_BusinessAcquisitionAxis=mmsi_VascularInsightsLLCandVIManagementInc.Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_BusinessAcquisitionAxis=mmsi_CiannaMedicalMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_ContingentConsiderationByTypeAxis=mmsi_AchievementofSupplyChainandScalabilityMetricsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_ContingentConsiderationByTypeAxis=mmsi_AnnualNetSalesMilestoneMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_BusinessAcquisitionAxis=mmsi_DirectACCESSMedicalLLCMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_BusinessAcquisitionAxis=mmsi_BectonDickinsonandCompanyMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_BusinessAcquisitionAxis=mmsi_ITLHealthcarePtyLtdMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_BusinessAcquisitionAxis=mmsi_LauraneMedicalS.A.S.Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_BusinessAcquisitionAxis=mmsi_OsseonLLCMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_BusinessAcquisitionAxis=mmsi_VascularAccessTechnologiesInc.Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_BusinessAcquisitionAxis=mmsi_ArgonMedicalDevicesInc.Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_BusinessAcquisitionAxis=mmsi_CatheterConnectionsInc.Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: